Cargando…
Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
BACKGROUND AND AIMS: Thrombolytic therapy is widely used to treat acute ischemic stroke (AIS) patients. As intracerebral hemorrhage is a life‐threatening complication of this therapy, monitoring the fibrinolytic and coagulation systems is imperative. However, existing studies on plasmin inhibitor co...
Autores principales: | Liu, Yonge, Ma, Jingting, Shi, Qiyang, Xin, Shimeng, Yu, Haojia, Liu, Zilong, Pang, Chunsong, Dong, Feng, Wang, Jinghan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752160/ https://www.ncbi.nlm.nih.gov/pubmed/33364440 http://dx.doi.org/10.1002/hsr2.218 |
Ejemplares similares
-
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016) -
Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke
por: Wang, Hai-rong, et al.
Publicado: (2015) -
Renal Dysfunction and Thrombolytic Therapy in Patients With Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
por: Hao, Zilong, et al.
Publicado: (2014) -
Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
por: Jung, Kee-Taig, et al.
Publicado: (2010) -
Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)